OR WAIT null SECS
April 01, 2020
Tools help improve understanding of excipient risk in formulating OSD drugs.
Understanding European GMPs and new rules from China for excipients are crucial for formulating solid-dosage drugs.
March 25, 2020
In light of the current COVID-19 pandemic, the agencies co-chaired the first global regulators meeting to facilitate development of vaccines against SARS-CoV-2, which causes COVID-19.
March 20, 2020
Emergent BioSolutions will help develop and manufacture an oral vaccine candidate and will develop plasma-based antibody therapeutics.
March 19, 2020
Synairgen, a respiratory drug discovery and development company, has announced that it has received expedited approvals to conduct a trial of its inhaled formulation of interferon-beta-1a, SNG001, in COVID-19 patients.
The partners have initiated an observational case-control study of siltuximab in patients with COVID-19 who have developed serious respiratory complications.
March 18, 2020
An NIH study of a COVID-19 vaccine is enrolling Seattle-based healthy adult volunteers.
March 11, 2020
Through the agreement, Emergent will manufacture the vaccine, which is formulated based on Novavax’s proprietary recombinant protein nanoparticle technology platform and its Matrix-M adjuvant to boost immune responses.
March 06, 2020
The new center expands the company’s R&D capabilities and will help it advance its portfolio of rare disease gene therapy programs.
March 05, 2020
Research from data and analytics company GlobalData shows that CAR-T cell therapy innovations across APAC will make the global market for these therapies more competitive.
